Presenter: Christine S. Moninghoff, Ph.D.
Online CME Credit
Fee: $0.00
Provides 2.00 hours of CE/CME credit (Presented on November 16, 2021; Reviewed October 31, 2022; Expires October 31, 2024)
Assessment, Diagnosis, and Treatment of Behavioral Health Problems in Children with Intellectual and Developmental Disabilities | Children's Behavioral Health Program Series
Overview
This session topic is part of a four-part series presented by the Nevada Department of Health and Human Services focused on the core elements of children's behavioral health. To view all session topics in this series, please click on the Nevada Department of Health and Human Services Children's Behavioral Health Program Series.
Learning Objectives
Following participation in this course, participants should be able to:
- Recognize what is meant by intellectual and developmental disability including discussing systems of support and examples of developmental disabilities
- Define particular needs related to family and community life including health, medical, education, vocation, and individual rights
- Describe how to access resources in the community to support the overall health and well-being of youth and adolescents with intellectual and developmental disabilities
Program Support
The State of Nevada, Division of Child and Family Services (D.C.F.S.) – Pediatric Mental Health Care Access Grant is responsible for payment to secure Continuing Medical Education (C.M.E.) units for these Online Training Videos. State of Nevada, DCFS – Pediatric Mental Health Care Access Grant staff will not profit in any way from participant viewing of these four Online Training Videos and Grant funds are managed in accordance with the ACGME Standards for Commercial Support.
This program is supported by Health Resources & Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $2,198,584 with 0% financed with non-governmental sources. The contents are those of the authors and do not necessarily represent the official views of HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.
Instructions for receiving CME/CE credit:
- Click on the registration button above
- Click on the course to register
- Pay for the course
- After payment, you will click begin the activity
- YouTube will be embedded into the website
- Watch the YouTube video
- Click to claim credit
- Enter the activity code that was provided to you in the email confirmation
- Claim credit and generate the certificate
Evaluation and Claim Credit
- Once you begin the video, you must watch it in its entirety to claim credit. Fast-forwarding has been disabled. You may pause the video briefly if needed. Do not close the browser window as doing so will require you to start over.
- Once you have reached the end of the video, a button to continue will appear that will take to evaluation and start the process for receiving a certificate.
- Failure to complete the process will result in the credit not being awarded to you.
- Should you need to restart the process, or download a copy of a certificate at a later time, please see the instructions for accessing the online portal here: Evaluation and Claim Credit
For questions concerning the online evaluation or your certificate, please contact our office at (775) 784-4791 or email us at cme@med.unr.edu.
Accreditation Designation Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the Nevada Department of Health and Human Services, Division of Child & Family Services – NV Pediatric Psychiatry Solutions. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 2.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Education Credit
The University of Nevada, Reno School of Medicine approves this program for 2.00 hours of nursing continuing education credit.
As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada, Reno School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, The University of Nevada, Reno School of Medicine requires that anyone in a position to control or influence the content of an accredited activity disclose all financial relationships within the prior 24 months with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. All relevant financial relationships have been mitigated. Following are those disclosures.
All other presenters, planners or anyone in a position to control the content of this continuing medical education activity have indicated that they do not have financial relationships with ineligible companies related to the content of this activity.
Aman, M.G. (2012). Aberrant Behavior Checklist: Current Identity and Future Developments. Journal of Clinical and Experimental Pharmacology, 2:3. https://doi.org/10.4172/2161‐1459.1000e114
Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A Child Behavior Rating Form for children with developmental disabilities. Research in Developmental Disabilities, 17, 41‐57.
Blankenship, K., Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010). Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6‐17 years. Pediatric health, 4(4), 375–381. https://doi.org/10.2217/phe.10.45
Chen, F., Grandjean, C., & Richard, S. Pharmacological management of inappropriate sexual behaviors in youth with autism spectrum disorder: A case study and review of the literature. (2016). Neuropsychiatrie de l’enfance et de l’adolescence, 64, 163‐167.
Cohen, D., Raffin, M., Canitano, R., Bodeau, N., Bonnot, O., Perisse, D., Consoli, A., & Laurent, C. (2013). Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta‐analysis of efficacy and secondary effects. Research in Autism Spectrum Disorders, 7, 167‐175. http://dx.doi.org/10.1016/j.rasd.2012.08.001
Developmental Disabilities Bulletin, 2008, Vol. 36, No.1&2, pp. 168‐198
Frazier, T.W. (2012). Friends not foes: Combined risperidone and behavior therapy for irritability in Autism [Editorial]. Journal of the American Academy of Child and Adolescent Psychiatry. 51(2), 129‐131.
Hellings, J. A., Boehm, D., Yeh, H. W., Butler, M. G., & Schroeder, S. R. (2011). Long‐term aripiprazole in youth with developmental disabilities including autism. Journal of Mental Health Research in Intellectual Disabilities, 4(1), 40‐52. DOI: 10.1080/19315864.2010.542274
Hieneman, M. (2015). Positive Behavior Support for Individuals with Behavior Challenges. Behavior Analysis in Practice, 8(1): 101‐108. doi: 10.1007/s40617‐0150051‐6 Retrieved from http://pbsnv@unr.edu
Intellectual disability. (n.d.). American Speech‐Language‐Hearing Association. Retrieved from https://www.asha.org/PRPSpecificTopic.aspx?folderid=8589942540§ion=Treatment
Journal of Autism and Developmental Disorders, 2011, Vol. 41, No.9, pp 1178‐1191 Journal of Child and Family Studies, 2013, Vol. 22, No.3, p 368‐369
Journal of Policy and Practice in Intellectual Disabilities, 2013, Vol. 10, No. 2, pp. 89‐92
Kaat, A. J., Zelko, F., Wilkening, G., & Berg, A. T. (2021). Evaluation of the Aberrant Behavior Checklist for Developmental and Epileptic Encephalopathies. Epilepsy & Behavior, 119, 107958. https://doi.org/10.1016/j.yebeh.2021.107958 Kendall, K., & Owen, M. J. (2018, May 26). Intellectual disability and psychiatric comorbidity:
Challenges and clinical issues. Psychiatric Times, 32(5). Retrieved from
http://www.psychiatrictimes.com/comorbidity‐psychiatry/intellectual‐disability‐and‐psychiatric‐comorbidity‐challenges‐and‐clinical‐issues Kuijper, D.G., Mulder, H., Evenhuis, H., Scholte, F., Visser, F., & Hoekstra, J.P. (2013). Determinants of physical health parameters in individuals with intellectual disability who use long‐term antipsychotics. Research in Developmental Disabilities, 34, 2799‐2809.
McQuire, C., Hassiotis, A., Harrison, B., & Pilling, S. (2015). Pharmacological interventions for challenging behaviour in children with intellectual disabilities: A systematic review and meta‐analysis. BMC Psychiatry, 15(303), 1‐13. DOI 10.1186/s12888‐015‐0688‐2 National Center for Health Statistics, 2020
Nevada Revised Statutes, 2019/2020 Norris, M., Aman, M. G., Mazurek, M. O., Scherr, J. F., & Butter, E. M. (2019). Psychometric characteristics of the aberrant behavior checklist in a well‐defined sample of youth with autism Spectrum disorder. Research in Autism Spectrum Disorders, 62, 1–9. https://doi.org/10.1016/j.rasd.2019.02.001
Perumal, N., Balan, N., & Stanfield, A. (2013). Psychopharmacology in children with intellectual disability and autism—across‐sectional analysis (2010). International
Journal of Developmental Disabilities. 59(1), 11‐19. Quebles, I., Solomon, O., Smith, K.A, Rao, S.R., Lu, F., Azen, C., Anaya, G., & Yin, L. (2020). Racial and ethnic differences in behavioral problems and medication use among children with Autism Spectrum Disorders. American Journal of Intellectual and Developmental Disabilities. 125(5), 369‐388.
Quintero, M. (2016). Co‐Occuring mental illness and developmental disabilities. Social Work Today, 10(5), 6. Retrieved from
https://www.socialworktoday.com/archive/092310p6.shtml
Ramerman, L., Hoekstra, P.J., & Kuijper, G. (2018). Exploring barriers and facilitators in the implementation and use of guideline recommendations on antipsychotic drug prescriptions for people with intellectual disability. Journal of Applied Research in Intellectual Disabilities. 31, 1062‐1070
Ramerman, L., Hoekstra, J.P., & Kuijper, D.G. (2018) Health‐related quality of life in people with intellectual disability who use long‐term antipsychotic drugs for challenging behavior. Research in Developmental Disabilities, 75, 49‐58.
Research Units on Paediatric Psychopharmacology Autism Network. (2005). Risperidone treatment of Autistic disorder: Longer‐term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry. 16, 1361–1369.
Reynolds, T., Zupanick, C. E., & Dombeck, M. (n.d.). Retrieved from https://www.mentalhelp.net/articles/therapies‐for‐intellectual‐disabilities‐and‐outdatedunproven‐treatments
Sainero, A., del Valle, J. F., Lopez, M., & Bravo, A. (2013). Exploring the specific needs of an understudied group: Children with intellectual disability in residential child care. Children and Youth Services Review, 35, 1393‐1399. http://dx.doi.org/10.1016/j.childyouth.2013.04.026
Sansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., Kaufmann, W. E., Berry‐Kravis, E., Lachiewicz, A., Brown, E. C., & Hessl, D. (2011). Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment. Journal of Autism and Developmental Disorders, 42(7), 1377–1392. https://doi.org/10.1007/s10803‐011‐1370‐2
Schmidt, J. D., Huete, J. M., Fodstad, J. C., Chin, M. D., & Kurtz, P. F. (2013). An evaluation of the Aberrant Behavior Checklist for children under age 5. Research in Developmental Disabilities, 34(4), 1190–1197. https://doi.org/10.1016/j.ridd.2013.01.002
Selecting Effective Treatments, A Comprehensive, Systematic Guide to Treating Mental Disorders by L Reichenberg, Lourie W. AuthorSeligman | Jan 26, 2016
Spreat, S., Conroy, J.W., & Jones, J.C. (1997). Use of psychotropic medication in Oklahoma: A statewide survey. American Journal on Mental Retardation. 102(1), 8085.
Tassé, M. J., Aman, M. G., Hammer, D., & Rojahn, J. (1996). The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Research in Developmental Disabilities, 17, 59‐75.
Unwin, L.G., & Deb, S. Efficacy of atypical antipsychotic medication in the management of behavior problems in children with intellectual disabilities and borderline intelligence: A systematic review. Research in Developmental Disabilities.(2011). 32, 2121‐2133.
Ylvisaker, M., Feeney, T., Hibbard, M., (2007). What Are Positive Behavior Supports? The Brain Injury Association of New York State. LEARNet